Strengthening R&D Capabilities
First written in FY2017-Q1. 20 of 31 entries say "Restated". Latest entry: FY2026.
112 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥8,514 million.」
Annual R&D expenses increased from ¥7,727 million in the previous fiscal year to ¥8,514 million, while performance improvements and functional enhancements for NXT R continued in Robot Solutions. - FY2025Annual R&D expenses of ¥7,727 million reportedAnnual report
「Total capital investment for the consolidated fiscal year was ¥14,801 million, including intangible fixed assets,」
R&D activities continued, with R&D expenses of ¥7,727 million reported for the consolidated fiscal year. In Robot Solutions, the company continued to focus on developing NXT R. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the interim consolidated fiscal year were ¥3,910 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated fiscal year.」
The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥3,910 million for the interim consolidated fiscal year. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative period of the current consolidated fiscal year were ¥6,209 million. There were no material changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no material changes in its R&D activities and reported cumulative R&D expenses of ¥6,209 million. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the six-month cumulative period of the current consolidated fiscal year were ¥4,072 million. There were no material changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥4,072 million for the cumulative period. - FY2024-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative period of the current consolidated fiscal year were ¥2,399 million. There were no material changes in the status of the Group's R&D activities during the three-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥2,399 million for the quarter. - FY2023Annual R&D expenses of ¥8,611 million reportedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥8,611 million.」
R&D activities continued, with annual R&D expenses of ¥8,611 million reported. Development of NXT R and AIMEX R was also described. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative period of the current consolidated fiscal year were ¥6,418 million. There were no material changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥6,418 million were reported, while the company stated that there were no material changes in the status of its R&D activities. - FY2023-Q2AdvancedAnnual report
「The company planned a ¥2,400 million capital investment to construct a new R&D building for subsidiary Fasford Technology Co., Ltd., scheduled for completion in December 2023. The method of financing had not been determined.」
The initiative to strengthen R&D capabilities was made concrete through the planned construction of a new R&D building for FFT, scheduled for completion in December 2023, involving planned capital investment of ¥2.4 billion. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative period of the current consolidated fiscal year were ¥2,225 million. There were no material changes in the status of the Group's R&D activities during the three-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥2,225 million for the quarter. - FY2022Annual R&D expenses of ¥8,107 million reportedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥8,107 million.」
R&D activities continued, with R&D expenses of ¥8,107 million reported for the fiscal year. - FY2022-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative period of the current consolidated fiscal year were ¥6,221 million. There were no material changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥6,221 million were reported, while the company stated that there were no material changes in the status of its R&D activities. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative period of the current consolidated fiscal year were ¥1,920 million. There were no material changes in the status of the Group's R&D activities during the three-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥1,920 million were reported, while the company stated that there were no material changes in the status of its R&D activities. - FY2021RaisedAnnual report
「R&D investment (¥ million) 10,000」
In addition to continuing R&D activities, the company explicitly set R&D investment of ¥10 billion as a target for the fiscal year ending March 2024 under its medium-term management plan. - FY2021-Q3AdvancedAnnual report
「In the machine tools field, we announced the GYROFLEX T4000 robot-equipped multitasking machine, which incorporates our advanced technologies in machine-tool cutting and automation.」
While maintaining the statement that there were no material changes in R&D activities, the announcement of the new GYROFLEX T4000 product in the machine tools field was cited as a specific achievement. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the six-month cumulative period of the current consolidated fiscal year were ¥4,300 million. There were no material changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥4,300 million were reported, while the company stated that there were no material changes in its R&D activities. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative period of the current consolidated fiscal year were ¥2,134 million. There were no material changes in the status of the Group's R&D activities during the three-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥2,134 million were reported, while the company stated that there were no material changes in its R&D activities. - FY2020RestatedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥8,803 million. We focused on developing the high-end NXT R model, equipped with the world's first automatic component replenishment system, with the aim of fully automating the electronic component placement process.」
R&D expenses of ¥8,803 million were reported, and high levels of R&D investment, including development of NXT R, continued. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative period of the current consolidated fiscal year were ¥6,469 million. There were no material changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥6,469 million were reported, while the company stated that there were no material changes in the status of its R&D activities. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the six-month cumulative period of the current consolidated fiscal year were ¥4,245 million. There were no material changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥4,245 million were reported, while the company stated that there were no material changes in the status of its R&D activities. - FY2020-Q1AdvancedAnnual report
「We announced the high-end NXT R model, equipped with the world's first automatic component replenishment system, with the aim of fully automating the electronic component placement process.」
The announcement of NXT R, equipped with the world's first automatic component replenishment system, was cited as a specific R&D achievement. - FY2019AdvancedAnnual report
「We focused on developing the high-end NXT R model, equipped with the world's first automatic component replenishment system, with the aim of fully automating the electronic component placement process.」
R&D expenses of ¥7,993 million were reported, and concrete development of NXT R progressed toward full automation of the electronic component placement process. - FY2019-Q3AdvancedAnnual report
「Total R&D expenses for the nine-month cumulative period of the current consolidated fiscal year were ¥5,914 million. Following the acquisition of FFT's shares and its conversion into a subsidiary on 31 August 2018, R&D activities related to semiconductor manufacturing equipment were added.」
R&D expenses of ¥5,914 million were reported, and R&D activities related to semiconductor manufacturing equipment were newly added following FFT's conversion into a subsidiary. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative period of the current consolidated fiscal year were ¥1,842 million. There were no material changes in the status of the Group's R&D activities during the three-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥1,842 million for the quarter. - FY2018RestatedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥8,349 million.」
R&D expenses of ¥8,349 million were reported, and development continued to enhance the functionality of the NXT series and prepare for the launch of the next strategic model. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative period of the current consolidated fiscal year were ¥6,387 million. There were no material changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥6,387 million were reported, while the company stated that there were no material changes in the status of its R&D activities. - FY2018-Q2RestatedAnnual report
「Total R&D expenses for the six-month cumulative period of the current consolidated fiscal year were ¥4,217 million. There were no material changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥4,217 million were reported, while the company stated that there were no material changes in the status of its R&D activities. - FY2018-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative period of the current consolidated fiscal year were ¥2,044 million. There were no material changes in the status of the Group's R&D activities during the three-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥2,044 million were reported, while the company stated that there were no material changes in the status of its R&D activities. - FY2017-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative period of the current consolidated fiscal year were ¥4,899 million. There were no material changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥4,899 million were reported, while the company stated that there were no material changes in the status of its R&D activities. - FY2017-Q2RestatedAnnual report
「Total R&D expenses for the six-month cumulative period of the current consolidated fiscal year were ¥2,992 million. There were no material changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
R&D expenses of ¥2,992 million were reported, while efforts to strengthen R&D capabilities continued. - FY2017-Q1First statedAnnual report
「i. Strengthening R&D capabilities」
Strengthening R&D capabilities is identified as one of the key medium-term initiatives.